Latest Breaking News On - Pproved plx us74365a3095 - Page 1 : comparemela.com

By Chris Wack Protalix BioTherapeutics and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, said Wednesday that the U.S. Food and Drug Administration has approved Elfabrio. | May 10, 2023

Chris wackDrug administrationChiesi groupProtalix biotherapeuticsChiesi global rare diseasesDow jonesNc stock exchangePress releasePproved plx us74365a3095